# Syapse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syapse

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.syapse.com
- Total disclosed funding: $157M
- Latest round: Series G (Feb 1, 2021)
- Investors on record: 14

## About

Syapse, Inc. is a biotechnology company focused on advancing precision medicine through its innovative clinical research solutions that integrate routine care and research, particularly in the field of oncology.Founded in 2008, Syapse, Inc. operates from its headquarters in San Francisco, US. The company specializes in providing solutions that enhance clinical trial processes in oncology and has successfully raised a total of USD 35.00 mn through multiple funding rounds, the most recent being a GROWTH round on July 27, 2022, led by Innovatus Capital Partners. The company was founded by Tony Loeser and is currently led by CEO Ken Tarkoff.Syapse, Inc. specializes in innovative solutions for accelerating drug development through its core offerings, including the First Always-On Clinical Research System in Community Oncology. This service integrates routine care with research, enabling oncologists to seamlessly incorporate clinical trials into everyday patient treatment. The company's research-ready network consists of purpose-built cohorts of standard-of-care patients, which facilitate phase II-to-phase III decision-making and enhance trial enrollment efficiency. Syapse’s platform supports comprehensive data collection methodologies, allowing for robust comparator groups and the integration of diverse patient populations, including underrepresented groups. The primary customer base includes community oncology practices across the United States, as well as pharmaceutical partners seeking to streamline their clinical trial processes and improve patient engagement in research.Syapse, Inc. generates revenue through partnerships with community oncology practices and pharmaceutical companies, facilitating a unique subscription-based model. The firm provides a comprehensive suite of services that includes tailored data collection programs for every patient, enhancing the operational efficiency of clinical trials. Transactions typically involve long-term agreements with healthcare providers, allowing access to Syapse's technology and research support services. Given its focus on embedding research into routine care, revenue streams are likely derived from ongoing contracts and operational fees associated with the deployment of its clinical research system. The company's flagship offerings, including N-Power Prospective External Controls and the Community Trial Accelerator, are designed to optimize the trial process, although specific pricing plans for these services are proprietary and not disclosed publicly.Following the most recent GROWTH round funding of USD 35.00 mn in July 2022, led by Innovatus Capital Partners, Syapse plans to leverage this capital to enhance its focus on providing real-world insights to its partners and improving outcomes for individuals with cancer. The company aims to develop new products that will further integrate clinical trials into routine oncology care. Additionally, Syapse is strategizing to expand its services into new regional markets within the United States to reach a broader audience of community oncology practices. This expansion is anticipated to take place within the next 18 months.

## Funding rounds

- Series G, Feb 1, 2021, $68M — Ally Bridge Group, Northpond Ventures
- Series F, May 28, 2020, $25M — Safeguard Scientifics, Amgen Ventures, Ascension Ventures, Merck Global Health Innovation Fund, Social Capital, Revelation Partners, Intermountain Ventures, Roche Finance Ltd.
- Series D, Nov 14, 2017, $30M — Safeguard Scientifics, Amgen Ventures, Ascension Ventures, Merck Global Health Innovation Fund, Roche Venture Fund, Social Capital, Medidata Solutions, Inc., GE Ventures, Intermountain Healthcare, Inc.
- Series C, Jan 8, 2016, $20M — Safeguard Scientifics, Ascension Ventures, Social Capital
- Series B, Jun 23, 2014, $10M — Safeguard Scientifics, Social Capital
- Series A, Jan 22, 2013, $4.8M — Social Capital

## Investors

- Social Capital (https://capitalatlas.ai/funds/social-capital) — Series A, Series B, Series C, Series D, Series F
- Safeguard Scientifics (https://capitalatlas.ai/funds/safeguard-scientifics) — Series B, Series C, Series D, Series F
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series C, Series D, Series F
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series D, Series F
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series D, Series F
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series D
- Medidata Solutions, Inc. — Series D
- GE Ventures — Series D
- Intermountain Healthcare, Inc. — Series D
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series F
- Intermountain Ventures (https://capitalatlas.ai/funds/intermountain-ventures) — Series F
- Roche Finance Ltd. — Series F
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series G
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series G